NYSE - Nasdaq Real Time Price USD

Bausch Health Companies Inc. (BHC)

Compare
6.21 +0.02 (+0.32%)
At close: September 6 at 4:00 PM EDT
6.34 +0.13 (+2.09%)
After hours: September 6 at 6:58 PM EDT
Loading Chart for BHC
DELL
  • Previous Close 6.19
  • Open 6.21
  • Bid 6.13 x 2200
  • Ask 6.24 x 3200
  • Day's Range 6.12 - 6.33
  • 52 Week Range 3.96 - 11.46
  • Volume 1,425,006
  • Avg. Volume 3,699,745
  • Market Cap (intraday) 2.289B
  • Beta (5Y Monthly) 0.75
  • PE Ratio (TTM) --
  • EPS (TTM) -1.29
  • Earnings Date Oct 31, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Nov 10, 2010
  • 1y Target Est 7.64

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

www.bauschhealth.com

20,270

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BHC

View More

Performance Overview: BHC

Trailing total returns as of 9/6/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BHC
22.57%
S&P/TSX Composite index
8.70%

1-Year Return

BHC
25.63%
S&P/TSX Composite index
11.60%

3-Year Return

BHC
78.83%
S&P/TSX Composite index
9.41%

5-Year Return

BHC
71.41%
S&P/TSX Composite index
37.45%

Compare To: BHC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BHC

View More

Valuation Measures

Annual
As of 9/6/2024
  • Market Cap

    2.29B

  • Enterprise Value

    23.35B

  • Trailing P/E

    --

  • Forward P/E

    1.51

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.25

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.54

  • Enterprise Value/EBITDA

    10.06

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.12%

  • Return on Assets (ttm)

    4.16%

  • Return on Equity (ttm)

    -2,304.54%

  • Revenue (ttm)

    9.2B

  • Net Income Avi to Common (ttm)

    -471M

  • Diluted EPS (ttm)

    -1.29

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    595M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    975.5M

Research Analysis: BHC

View More

Company Insights: BHC

Research Reports: BHC

View More

People Also Watch